Physician profile
Mark C Tekrony
NPI 1386613826
$3,794.07
in general payments reported to CMS, 2019-2025
36 companies · $826 in 2025
The $826 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $503 · 2020: $379 · 2021: $418 · 2022: $473 · 2023: $331 · 2024: $864 · 2025: $826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,021.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,020.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,001.87 | 2019-2022 | |
| Abbvie INC. | $744.54 | 2021-2025 | Qulipta, Ubrelvy |
| Harmony Biosciences LLC | $308.84 | 2023-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $262.33 | 2019-2025 | |
| Lundbeck LLC | $179.21 | 2019-2025 | Vyepti |
| Lilly USA, LLC | $118.16 | 2023-2025 | Amyvid, Emgality, Reyvow |
| Merz Pharmaceuticals, LLC | $113.58 | 2022-2025 | Inbrija, Xeomin, Ampyra |
| Axsome Therapeutics, INC. | $86.67 | 2024-2025 | Sunosi, Symbravo |
| Avadel Cns Pharmaceuticals, LLC | $86.08 | 2024-2025 | Lumryz |
| Novartis Pharmaceuticals Corporation | $85.75 | 2019-2024 | |
| Supernus Pharmaceuticals, INC. | $68.97 | 2019 | |
| Eisai INC. | $64.20 | 2021-2025 | |
| Argenx US, INC. | $56.14 | 2023-2024 | Vyvgart Hytrulo |
| Pfizer INC. | $55.21 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $48.93 | 2025 | Quviviq |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $46.66 | 2019-2024 | Rystiggo |
| Revance Therapeutics, INC. | $38.83 | 2024 | Daxxify |
| Life Molecular Imaging Ltd | $36.52 | 2025 | Neuraceq |
| Inspire Medical Systems, INC. | $33.16 | 2025 | Inspire |
| Upsher-Smith Laboratories LLC | $31.16 | 2020 | |
| Alexion Pharmaceuticals, INC. | $29.38 | 2022 | |
| Tg Therapeutics, INC. | $27.55 | 2025 | |
| Allergan, INC. | $27.00 | 2019-2020 | |
| Noctrix Health, INC. | $26.08 | 2025 | Nidra |
| Genentech USA, INC. | $24.35 | 2025 | Ocrevus Zunovo |
| Amgen INC. | $24.03 | 2019 | |
| Cycle Pharmaceuticals INC | $23.58 | 2024 | Tascenso Odt |
| Sunovion Pharmaceuticals INC. | $19.94 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.96 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $17.02 | 2024 | Dysport |
| Amneal Pharmaceuticals LLC | $16.98 | 2019 | |
| Celgene Corporation | $15.86 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $15.10 | 2024 | Wainua |
| Biogen, INC. | $14.89 | 2020 | |
| Emd Serono, INC. | $14.24 | 2019 | |
| Itamar Medical INC | $12.30 | 2025 | Watchpatone |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Tekrony listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.